Treatment for chronic atrophic gastritis using a modified herbal decoction
Clinical Study on the Efficacy of Modified Liujunzi Prescription on the Treatment of Atrophic Gastritis After HP Eradication
This study is testing if a special herbal treatment can help people with chronic atrophic gastritis feel better after they’ve cleared a stomach infection, compared to standard treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 286 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Peking University First Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT05388890 on ClinicalTrials.gov |
What this trial studies
This observational cohort study aims to evaluate the efficacy and safety of Modified Liujunzi Decoction in patients with chronic atrophic gastritis (CAG) who have undergone Helicobacter pylori eradication. The study will compare the outcomes of patients receiving this herbal treatment against those receiving routine treatment with Weifuchun. A total of 284 patients will be included, and their curative efficacy, symptom scores, and any adverse events will be recorded and analyzed to provide evidence for effective CAG treatment and potentially reduce gastric cancer risk.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-70 with a diagnosis of chronic atrophic gastritis confirmed by endoscopy and pathology, who have previously been treated for Helicobacter pylori infection.
Not a fit: Patients with a history of gastric surgery or serious concurrent diseases such as liver, heart, or kidney disease may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could offer a novel and effective approach to managing chronic atrophic gastritis and reducing the risk of gastric cancer.
How similar studies have performed: While this approach is based on traditional Chinese medicine, similar studies have shown promise in treating gastrointestinal conditions, but this specific methodology is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with CAG diagnosed by endoscopy and pathological examination, the pathological diagnosis criteria refer to the China consensus of chronic gastritis (2017) ; * Previous HP infection, HP negative after standardized treatment; * TCM syndrome differentiation mainly focuses on the weakness of the spleen and stomach,referring to the consensus on the diagnosis and treatment of chronic atrophic gastritis with integrated traditional Chinese and Western Medicine (2017), there is no restriction on concurrent syndrome; * Age 18-70 years old, regardless of gender; * The subject (or legal representative) voluntarily agreed and signed the informed consent form, and was able to abide by the study protocol during the study. Exclusion Criteria: * History of gastric surgery; * Combined with serious diseases affecting the study evaluation, such as serious liver disease, heart disease, kidney disease, malignant tumor and alcoholism; * Allergic to the drugs used in this study; * Participated in clinical research of other drugs in the first 3 months of the study; * Patients can't express correctly their subjective feelings and can't cooperate.
Where this trial is running
Beijing, Beijing
- Peking University First Hospital — Beijing, Beijing, China (Recruiting)
Study contacts
- Study coordinator: Qiuyue Huang, doctor
- Email: 1711210349@pku.edu.cn
- Phone: +86010 83572351
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.